Cardiovascular toxicities associated with immune checkpoint inhibitors (vol 115, pg 854, 2019)

被引：25

作者：

Hu, Jiun-Ruey

Florido, Roberta

Lipson, Evan J.

Naidoo, Jarushka

Ardehali, Reza

Tocchetti, Carlo G.

Lyon, Alexander R.

Padera, Robert F.

Johnson, Douglas B.

Moslehi, Javid

机构：

[1] Division of Cardiology, Cardio-Oncology Program, Vanderbilt University Medical Center, 2220 Pierce Avenue, Nashville

[2] Division of Cardiology, Johns Hopkins University School of Medicine, 600 N Wolfe St, Baltimore, MD

[3] Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, 1550 Orleans Street, Baltimore, MD

[4] Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, MD

[5] Division of Cardiology, David Geffen School of Medicine, University of California Los Angeles, 675 Charles E Young Dr S, Los Angeles, CA

[6] Department of Translational Medical Sciences, Interdepartmental Center for Clinical and Translational Research (CIRCET), Federico II University, Via Pansini 5, Naples, NA

[7] Cardio-Oncology Service, Royal Brompton Hospital, Dovehouse St, London

[8] National Heart and Lung Institute, Imperial College London, Sydney Street, London, UK

[9] Department of Pathology, Brigham and Women's Hospital, 75 Francis St, Boston, MA

[10] Division of Hematology-Oncology, Vanderbilt University Medical Center, 2220 Pierce Avenue, Nashville, TN

来源：

CARDIOVASCULAR RESEARCH | 2019年 / 115卷 / 05期

关键词：

Cardio-oncology; Cardiovascular toxicity; Immune checkpoint inhibitors; Myocarditis; Pericarditis; Vasculitis;

D O I：

10.1093/cvr/cvz082

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cardiovascular toxicities associated with immune checkpoint inhibitors (ICIs) have been reported in case series but have been underappreciated due to their recent emergence, difficulties in diagnosis and non-specific clinical manifestations. ICIs are antibodies that block negative regulators of the T cell immune response, including cytotoxic T lymphocyte-associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), and PD-1 ligand (PD-L1). While ICIs have introduced a significant mortality benefit in several cancer types, the augmented immune response has led to a range of immune-related toxicities, including cardiovascular toxicity. ICI-associated myocarditis often presents with arrhythmias, may co-exist with myositis and myasthenia gravis, can be severe, and portends a poor prognosis. In addition, pericardial disease, vasculitis, including temporal arteritis, and non-inflammatory heart failure, have been recently described as immune-related toxicities from ICI. This narrative review describes the epidemiology, diagnosis, pathophysiology, and treatment of cardiovascular toxicities of ICI therapy, highlighting recent developments in the field in the past year. © 2019 OUP.All rights reserved.

引用

页码：868 / 868

页数：1